Table 2 Received primary therapeutic agent (PTA) in the study population, n = 329
Drug or treatment regimen | No. of patients (%) | Mean daily dose mg* | CPZ equivalents mg** |
|---|---|---|---|
Second generation antipsychotic (SGA) | 305 (92.7%) | ||
Olanzapine | 104 (31.6%) | 14.4 | 288 |
Risperidon or Risperdal Consta | 41 (20.6%) | 3.7 | 244 |
Quetiapine | 58 (17.6%) | 537,5 | 698 |
Aripiprazole | 51 (15.5%) | 14.2 | 189 |
Ziprasidon | 20 (6.1%) | 85.8 | 137 |
Amisulpride | 11 (3.3%) | 615.9 | 616 |
Clozapine | 16 (4.8%) | 390.6 | 391 |
Sertindole | 4 (1.2%) | 18.2 | 342 |
First generation antipsychotic (FGA) | 24 (7.3%) | ||
Perphenazine or Perphenazine decan. | 12 (3.6%) | 8.9 | 111 |
Zuclopenthixol or Zuclopenthixol decan. | 6 (2.1%) | 20.0 | 80 |
Chlorprothixen | 3 (0.9%) | 116.7 | 233 |
Levomepromazine | 1 (0,3%) | 120 | 120 |
Chlorpromazine | 1 (0.3%) | 30.0 | 120 |
Flupentixol | 1 (0.3%) | 1.0 | 50 |
Haloperidol | 0 (0%) | ||
No. of patients using only one antipsychotic drug | 228 (69.3%) | ||
No. of patients using more than one antipsychotic drug | 101 (30.7%) |